Medical/Pharmaceuticals

Biocytogen Enters into Antibody Agreement with Merck

BEIJING, April 29, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) announced that it has entered into an evaluation and option agreement with Merck to grant them a sole license to evaluate Biocytogen's proprietary antibodies against at least three distinct targets...

2022-04-29 20:00 3470

New IFPA report reveals link between psoriatic disease and mental health

STOCKHOLM, April 29, 2022 /PRNewswire/ -- Psoriatic disease is an inflammatory illness that affects the skin and joints. Itchy, flaky patches of skin are perhaps the most common symptom. But psoriatic disease goes far deeper. For many, one of the most difficult challenges in living with psoriatic...

2022-04-29 14:00 3751

Asia Pacific Initiative on Reproduction (ASPIRE) 2022 Congress: Greater sense of patient empowerment with telemedicine trends in IVF services

SINGAPORE, April 29, 2022 /PRNewswire/ -- Telemedicine that became a vital engagement tool between health professionals and patients during the COVID-19 pandemic is emerging as a welcome new treatment of choice among fertility clinics and couples striving for parenthood. Patients seeking assiste...

2022-04-29 10:50 5229

Transcenta to Present Clinical Trial Data of TST001 and MSB0254 at 2022 ASCO Annual Meeting

SUZHOU, China, April 29, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the abstracts o...

2022-04-29 10:33 4423

I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer

-  Biotech and Wall Street veteran Mr. Richard Yeh to focus on strategic investor interactions, global alliance management and facilities as COO -  Renowned oncology expert Dr. John Hayslip to further accelerate global clinical development of I-Mab's innovative pipeline as CMO SHANGHAI and GAITHE...

2022-04-29 04:01 2528

Promising COVID oral antiviral being co-researched by Healion Bio and FUJIFILM Toyama

FREDERICK, Md., April 29, 2022 /PRNewswire/ -- Healion Bio, a closely held biotechnology company, today announced a collaborative agreement to research a combination antiviral against SARS-CoV-2 and other deadly pathogens. The combination will include one of Healion Bio's protease inhibitors and ...

2022-04-29 01:00 2949

Varian partners with Icon Group to advance patient-centric solutions

Bringing clinical insights into early product development PALO ALTO, Calif. and SYDNEY, April 28, 2022 /PRNewswire/ -- Varian, a Siemens Healthineers company (Varian), today announced a five-year research and professional services agreement with Icon Group (Icon). Through this agreement, Icon wi...

2022-04-28 23:00 2822

Gracell Biotechnologies Announces Details of Oral Abstract Presentation at 2022 ASCO Annual Meeting

Gracell to present longer-term follow-up clinical data evaluating GC012F, an autologous CAR-T therapeutic candidate dual-targeting BCMA and CD19, for the treatment of relapsed/refractory multiple myeloma SAN DIEGO, Calif. and SUZHOU, China, April 28, 2022 /PRNewswire/ -- Gracell Biotechnologies ...

2022-04-28 22:30 2874

Lunit to Present 11 Abstracts at the 2022 ASCO Annual Meeting

* 7 poster presentations and 4 online publications, including research on AI biomarkers, have been accepted by ASCO * Findings demonstrate the practical effectiveness of Lunit's AI solution in the pathological assessment of cancer SEOUL, South Korea, April 28, 2022 /PRNewswire/ -- Lunit today...

2022-04-28 21:33 2317

Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment after Cataract Surgery at ARVO 2022 Annual Meeting

TAIPEI, April 28, 2022 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWO.6838 ) and Aimmax Therapeutics, Inc. ( United States) announced that results from a Phase 2 clinical study of APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension), a novel ...

2022-04-28 20:00 2366

HanAll Biopharma Reports First Quarter 2022 Results and Provides Business Update

* HanAll will expand R&D investments to advance its late-stage pipeline assets   SEOUL, South Korea, April 28, 2022 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), a global biopharma company committed to deliver innovative and impactful therapeutics to address severe unmet medical needs, tod...

2022-04-28 19:00 2443

United Imaging Healthcare bags Healthcare Asia Medtech Award

SHANGHAI, April 28, 2022 /PRNewswire/ -- United Imaging Healthcare was recognised with the Imaging Product Innovation of the Year Award at the Healthcare Asia Medtech Awards with its three groundbreaking products: the Total-body PET/CT uEXPLORER, the 3.0T uMR Omega, and uRT-linac 506c. United Im...

2022-04-28 18:28 4956

Transcenta Announces First Patient Dosed in China Study of Anti-sclerostin Monoclonal Antibody TST002 for the Treatment of Osteoporosis

SUZHOU, China, April 28, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the successful dosin...

2022-04-28 17:06 3393

The Danish National Genome Center Partners with Lifebit to Deliver Nationwide Personalised Medicine

The Danish National Genome Center has awarded Lifebit a four-year contract to implement Lifebit's Federated Trusted Research Environment software, Lifebit CloudOS, withinDenmark's national supercomputing center. LONDON, April 28, 2022 /PRNewswire/ -- Lifebit, whose leading technology enable...

2022-04-28 14:00 5148

WuXi Biologics' 2021 ESG Report Reveals Company's Strong Commitment to Overall Sustainability

-   WuXi Biologics has aligned its ESG strategy with the United Nations Sustainable Development Goals (SDGs), as well as with its stakeholders' interests in sustainable business performance. -   One example of WuXi Biologics' contribution to society is its rapid, robust pandemic response -- enab...

2022-04-28 08:30 2768

ASCO 2022 | Ascentage Pharma to Present Data from Seven Clinical Studies at the 2022 American Society of Clinical Oncology Annual Meeting

SUZHOU, China, and ROCKVILLE, MD, April 27, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that updated results from seven studies involving...

2022-04-28 08:18 2329

HealthBeats Raises US$3m Seed Funding Led By Heritas Capital And SEEDS Capital To Expand Remote Vitals Monitoring In Australia And Singapore

SINGAPORE and SYDNEY and NEW YORK, April 28, 2022 /PRNewswire/ -- HealthBeatsTM , aSingapore-based healthtech start-up with end-to-end remote vitals monitoring solution, today announced the close of aUS$3m Seed round led by healthcare investor Heritas Capital together with SEEDS Capital, the inves...

2022-04-28 08:15 3154

CStone to present the latest clinical results of anti-PD-L1 antibody sugemalimab and anti-PD-1 antibody nofazinlimab at ASCO 2022

* Results from GEMSTONE-201 study of sugemalimab, the first successful registrational clinical study to date evaluating an anti-PD-(L)1 antibody targeting patients with relapsed or refractory extranodal natural killer/T-cell lymphoma, will be presented in an oral abstract session * The protoc...

2022-04-28 08:00 4073

Zimmer Biomet's mymobility is recognized as "The Care Management Initiative of the Year" by the 2022 Healthcare Asia Medtech Awards

SINGAPORE, April 28, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that the company's mymobility® digital care management platform won "The Care Management Initiative of the Year" award at this year's Healthcare Asia Med...

2022-04-28 08:00 5698

Glooko Appoints Alfonso "Chito" Zulueta, former Eli Lilly & Company Senior Executive, to Board of Directors

PALO ALTO, Calif., April 28, 2022 /PRNewswire/ -- Glooko, Inc., a leading provider of remote patient monitoring and data management solutions for diabetes and related chronic conditions, today announced the appointment of Alfonso "Chito" Zulueta to its Board of Directors. Respected as a leader w...

2022-04-28 07:00 4803
1 ... 563564565566567568569 ... 643